Sharekhan's research report on Mastek
The company expects the US geography, Data & automation, AI service line and the Healthcare vertical to grow above the company’s average growth, with the growth in US geography and Data & Automation service line expected to be driven by organic growth, account mining, and BizAnalytica, while growth in Healthcare vertical is expected to be driven by improvement in NHS, pipeline deals, and new opportunities. Opportunities due to policy changes, greater Cloud adoption by UK public sector departments and participation in emerging frameworks would further boost the core UK public sector that is already witnessing strong order booking. EBITDA margin is likely to gradually recover to 17-19% in the coming quarters on push from US growth, improving BizAnalytica margins, and implementation of various measures to aid margin recovery.
Outlook
We maintain Buy with revised price target (PT) of Rs 3,235 (increase in PT reflects increase in target multiple to22x) owing to possible improvement in NHS, strong order booking in the resilient UK public sector, coupled with strong US growth profile and account mining efforts which will offer stronger revenue visibility for FY25 and aid in industry leading growth in addition to recovery in margin profile. At the CMP the stock trades at 23.8/18.8x its FY25/26E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.